Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Alfa Cytology's integrated CRO solutions streamline your R&D process.
Leukemia are blood cancers of which there are several variants and corresponding features. It’s this variation that leads scientists to design special treatments for each one.
Comprehensive Leukemia Specialist
PROTEIN KINASE INHIBITORs are being developed as new anti-tumor treatments to inhibit dysregulated signal transduction in leukemia.
IMMUNE CHECKPOINT INHIBITORs have been engineered as therapies for immune checkpoint failure in leukemia cells and immune escape in the cancers.
>> View details
HYPOMETHYLATING AGENT DEVELOPMENT may provide innovative solutions for breakthrough approaches to leukemia research and therapy, since gene mutations that involve methylation are implicated in the condition.
HEDGEHOG PATHWAY INHIBITORs suppress the overexpression of the Hedgehog (Hh) signaling pathway in leukemia, which is associated with the maintenance of leukemia stem cells, thereby affect the outcome of patients.
TARGETED DRUG DEVELOPMENT AGAINST HTLV-1 to find innovative treatments and improve prognosis for adult T-cell leukemia (ATL).
LEUKEMIA CELL SURFACE ANTIGENs play an important role in diagnosing and classifying the disease and can also serve as binding sites for the development of targeted therapeutic approaches.
Beginning with an initial consultation, we get a deep insight into your specific project requirements to make sure our services are completely compatible with your goals and compliances.
Following discussion, we build you a one-to-one proposal for scope, approach, timeline and costing, specifically suited to your drug development needs.
Preclinical drug development and validation is carried out by our team using advanced tools and techniques. All the way through, we have strict quality assurance processes so that the output can be reliable and accurate.
Once the project is complete, we deliver a full report including all of the results, expert insights and takeaways. We validate that the report is as promised to you and meets all regulatory expectations before finalizing.
We do not stop after you have finished your project, we will support you with the next analysis or changes as your project evolves.
Select Services of Interest
Taylor B., Director of Product Development
Josh K., Chief Scientific Officer